Zacks Investment Research upgraded shares of Avant Diagnostics (OTCMKTS:AVDX) from a hold rating to a buy rating in a research report report published on Tuesday, Zacks.com reports. They currently have $15.00 price target on the stock.
According to Zacks, “AvidXchange Holdings Inc. is a provider of accounts payable automation software and payment solutions for middle market businesses and suppliers. The company’s software-as-a-service-based, end-to-end software and payment platform digitizes and automates the AP workflows for businesses and supplier. AvidXchange Holdings Inc. is based in CHARLOTTE, N.C. “
Several other research analysts have also recently weighed in on the stock. Barclays initiated coverage on shares of Avant Diagnostics in a research report on Monday, November 8th. They issued an overweight rating and a $29.00 price objective for the company. The Goldman Sachs Group dropped their price objective on shares of Avant Diagnostics from $35.00 to $28.00 and set a buy rating for the company in a research report on Monday, December 13th. Deutsche Bank Aktiengesellschaft started coverage on shares of Avant Diagnostics in a research report on Monday, November 8th. They issued a buy rating and a $30.00 price objective for the company. JPMorgan Chase & Co. started coverage on shares of Avant Diagnostics in a report on Monday, November 8th. They set an overweight rating and a $28.00 target price for the company. Finally, KeyCorp started coverage on shares of Avant Diagnostics in a report on Monday, November 8th. They set an overweight rating and a $30.00 target price for the company. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of Buy and a consensus price target of $27.20.
Avant Diagnostics (OTCMKTS:AVDX) last posted its quarterly earnings data on Tuesday, November 16th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.57). The company had revenue of $65.18 million for the quarter, compared to analysts’ expectations of $61.55 million. Avant Diagnostics’s revenue was up 36.9% on a year-over-year basis.
About Avant Diagnostics
Avant Diagnostics, Inc, a commercial-stage molecular data-generating company, focuses on the development and commercialization of proprietary data-generating assays that provide information for physicians and patients in the areas of cancers. It owns license and distribution right for OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer.
Further Reading: The primary rules of Elliott Wave theory
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avant Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avant Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.